Search
Hisun Secures FDA Approval for Clinical Trials of Innovative Drug HSK47977 Tablets
2025-09-01 /
Read about 0 minute
Author：小编
Hisun Pharmaceuticals has recently announced a significant milestone: its proprietary oral BCL6 PROTAC small molecule formulation, HSK47977 tablets, has received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA). This approval paves the way for the initiation of clinical trials for the drug, which is specifically designed to treat lymphoma. Notably, in August, HSK47977 tablets also received approval for clinical trials from China's National Medical Products Administration, and the enrollment of the first subject was successfully completed.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
